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JunB is important in maintaining normal hematopoietic stem cell functions, but the mechanisms underlying
its activity are not well understood. In the current issue of Cancer Cell, a study by Santaguida et al. provides
new insights into JunB’s function and the genesis of myeloid disease.Previous studies have indicated a role for
JunB in the maintenance and preservation
of normal hematopoietic stem cell (HSC)
functions (Passegue´ et al., 2001, 2004).
In this issue of Cancer Cell, Santaguida
et al. (2009) now provide a detailed cellular
and molecular analysis of junB-deficient
stem cells, which indicates that JunB
functions to limit both cell-cycle entry
and myeloid differentiation. Furthermore,
in the course of their work, the investiga-
tors demonstrate some important limita-
tions to the utility and interpretation of
transplantation-based stem cell functional
assays. Thus, their study provides not only
new information about JunB but also
some key considerations for analyses of
HSCs.
Nearly 30 years ago, David Harrison first
coined the term ‘‘competitive repopula-
tion’’ to describe the assay that has since
become the gold standard for functional
analysis of HSCs (Harrison, 1980).
Although variations on the method have
emerged in recent years, the basic prin-
ciple remains unchanged. By comparing
the engraftment potential of an unknown
source of HSCs to a known source of
HSCs (in the same transplanted recipient
animal), one can quantitatively estimate
the frequency of stem cells in the unknown
fraction. Experimentally, one transplants
different ratios of HSCs from an unknown
source and HSCs from a known source
into appropriately conditioned recipient
animals, typically by mixing different
numbers of cells from an unknown source
with a fixed number of cells from a known
source (competitor). Using phenotypically
distinct populations of known and
unknown cells provides a simple means
by which to determine the relative contri-252 Cancer Cell 15, April 7, 2009 ª2009 Elsebution of each stem cell source to repopu-
lation of the hematopoietic system. A
major advantage of this method is that it
does not require purification of HSCs but
rather can be performed using bulk popu-
lations, generally derived from bone
marrow. Because only HSCs durably
persist in vivo, while other more mature
cell types turn over relatively quickly, by
simply waiting an appropriate period of
time, the constituent cells in a repopulated
host are known to have derived from the
stem cell source.
The competitive repopulation method
has been used by countless investigators
to assess the relative frequency and func-
tional properties of HSCs and is arguably
the most valuable tool researchers have
for determining the in vivo potential of
stem cell populations. Naturally, as molec-
ular genetic methods have become more
prevalent in recent years, virtually every
mutation or genetic change relevant to
HSCs has been investigated using this
approach (Zon, 2008). However, as shown
by Santaguida et al. in this issue, results
from this assay can be more difficult to
interpret than previously appreciated. In
characterizing the properties of HSCs,
these investigators initially observed
reduced functional capacity of junB-
deficient cells in standard competitive
repopulation assays. Such findings would
generally be viewed as clear evidence
that the activity of JunB is required for
some basic stem cell function, such as
self-renewal or homing. However, to their
credit, the investigators delved much
deeper into this problem and performed
a detailed series of studies to better under-
stand the nature of junB deficiency. In so
doing, they discovered that highly en-vier Inc.riched populations of HSCs (defined using
the so-called ‘‘SLAM’’ markers) (Kiel et al.,
2005) are in fact entirely normal in junB-
deficient animals, but their presence is
essentially masked by an overproduction
of myeloid progenitors (Figure 1). Indeed,
the relative abundance of progenitors,
and even quiescent cell types within the
primitive compartments, appeared to
result in dilution of true long-term repopu-
lating HSCs (LT-HSCs) when the overall
marrow population was evaluated on
a per cell basis. Collectively, the data
indicate that loss of JunB does not impair
the functional properties of LT-HSCs
but rather skews early developmental
programs such that their relative
frequency is altered. In addition, these
studies clearly demonstrate the impor-
tance of using highly enriched populations
of LT-HSCs for competitive repopulation
studies and suggest that it may be
necessary to reevaluate findings from
previous reports in which HSC functions
were characterized using nonpurified cell
populations (Zon, 2008).
Aside from developmental aberrancies
in junB-deficient HSCs, Santaguida et al.
also found a striking increase in prolifera-
tion rates. In comparison to normal cells,
almost double the proportion of junB-
deficient LT-HSCs underwent cell-cycle
entry each day, suggesting that JunB
functions to limit cell-cycle entry in
primitive populations. Gene expression
analyses revealed that junB-deficient
LT-HSCs had increased expression of cy-
clins and decreased expression of cyclin-
dependent kinase inhibitors, suggesting
that the absence of JunB induces other-
wise quiescent cells to enter the cell cycle
at a higher frequency. In many previous
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PreviewsFigure 1. Competitive Repopulation Assays and Hematopoietic Stem Cell Frequency
Studies in normal hematopoietic cells (top) are typically performed with either unfractionated bone marrow (BM) or enriched stem cell populations (blue panel at
right). In perturbed genetic systems, such as junB-deficient mice (bottom), higher proliferation and/or skewed differentiation cause an increased pool of myeloid
progenitors. The accumulation of such cells can lead to erroneous conclusions when nonpurified populations are used for the assay (blue panel at right). Using the
same assays with highly purified LT-HSC populations (green panel at left), Santaguida et al. (2009) revealed that there are no functional differences in the LT-HSCs
of junB-deficient mice in comparison to wild-type controls. HSPC, hematopoietic stem and progenitor cell; MPD, myeloproliferative disease.studies, it has been reported that
mutations causing increased cycle rate
typically result in so-called stem cell
‘‘exhaustion’’ (Miller and Van Zant, 2006).
However, as shown by Santaguida et al.,
junB-deficient LT-HSCs have regenera-
tive potential similar to control stem cells,
with the only notable difference being
higher levels of myeloid reconstitution.
This surprising finding contradicts the
long-standing notion that cycle activa-
tion/entry of HSCs is associated with
loss of their functional potential (Quesen-
berry et al., 2007).
Given the observations noted above,
the challenge for these investigators was
to provide a mechanism explaining how
JunB could simultaneously orchestrate
the increases in cell-cycle rate and myelo-
poiesis while maintaining stem cell func-
tions. To this end, their molecular studiesled to the identification of two important
JunB-mediated signaling pathways that
appear to regulate homeostasis of the
hematopoietic system. They found that
Notch and TGF-b pathways inhibit the
differentiation of LT-HSCs to myeloid
progenitors by acting through a common
target, Hes1, the expression of which is
dependent on JunB. Therefore, junB-defi-
cient cells cannot respond to Notch and
TGF-b signals that limit cycle rate and
myeloid differentiation. These findings
provide important insight into possible
early stages of the leukemogenic process.
Indeed, it is attractive to speculate that the
first steps of leukemic transformation
involve very primitive cells undergoing
mutations that cause loss of control over
growth and differentiation. The resulting
increase in cycle rate and myelopoiesis
would then lead over time to myeloprolif-Cancer Ceerative disease. Presumably, further
genetic or epigenetic alterations in the
aberrantly accumulating clones could
then give rise to a fully malignant leukemic
stem cell that would be sufficient to
produce and maintain acute leukemia.
Taken together, the studies by Santa-
guida et al. have provided a valuable
lesson on the interpretation of classical
stem cell biology assays in genetically
modified systems, described new insights
into the role of JunB in HSC biology, and
provided exciting clues as to the early
pathogenesis of leukemia stem cells.
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